Clinical Trial Search

Primary: Safety: Number of Participants With Grade 3 or Grade 4 Adverse Events (AEs) and Laboratory Abnormalities Defined as Dose Limiting Toxicities (DLT) (Phase 1a) — 0; 0; 1…

Primary: Number of Participants Experiencing Adverse Events (AEs) in Part 1 — 5; 5; 1; 4 Participants

Primary: Period 1: Absolute Bioavailability Based on Ratio of Dose Normalized Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC∞ ) for TAK-906 — 9.12…

Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 7; 2 Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms — 5; 10; 6; 3 Participants

Primary: Number of Participants With Local and Systemic Adverse Events (AEs) Through 29 Days Post-vaccination With Bris10 M2SR and Cumulatively Through Day 209 — 28; 24…

Primary: Cohort 1: Maximum Observed Concentration (Cmax) of Gepotidacin in Plasma — 4.817; 4.548 Micrograms per milliliter

Primary: Maximum Total Plasma Concentration (Cmax) — 28.7 mg/L

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 1; 0; 2 Participants

Primary: Number of Subjects With Solicited Local Adverse Events (AEs) After First Dose of Vaccination — 1; 0; 17; 1 Participants

Primary: Percentage of Participants With Drug-related Adverse Events (AEs) — 0.0; 12.5; 12.5; 50.0 Percentage of participants (%)

Primary: Percentage of Participants With Drug-related Adverse Events (AEs) — 0; 0; 0; 16.7 Percentage of participants (%)

Primary: Number of Participants Who Experienced at Least 1 Adverse Event (AE): All Parts — 2; 1; 3; 5 Participants

Primary: Number of Participants With 50% Reduction in Corticosteroid Requirement — 3 Participants

Primary: Percentage of Participants With Solicited Local Injection Site Reactions by Severity Within 7 Days After Dose 1 of PIZV or Placebo — 13.3; 30.0; 32.3; 38.7 percentage of…